|Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study|
AR Mato, NN Shah, W Jurczak, CY Cheah, JM Pagel, JA Woyach, ...
The Lancet 397 (10277), 892-901, 2021
|Outcomes of COVID-19 in patients with CLL: a multicenter international experience|
AR Mato, LE Roeker, N Lamanna, JN Allan, L Leslie, JM Pagel, K Patel, ...
Blood, The Journal of the American Society of Hematology 136 (10), 1134-1143, 2020
|Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy|
TA Eyre, HS Walter, S Iyengar, G Follows, M Cross, CP Fox, A Hodson, ...
Haematologica 104 (2), e68, 2019
|Real-world experience with caplacizumab in the management of acute TTP|
T Dutt, RJ Shaw, M Stubbs, J Yong, B Bailiff, T Cranfield, MP Crowley, ...
Blood, The Journal of the American Society of Hematology 137 (13), 1731-1740, 2021
|Assessment of the efficacy of therapies following venetoclax discontinuation in CLL reveals BTK inhibition as an effective strategy|
AR Mato, LE Roeker, R Jacobs, BT Hill, N Lamanna, D Brander, ...
Clinical Cancer Research 26 (14), 3589-3596, 2020
|Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients|
haematologica 101 (12), 1563, 2016
|Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study|
JJ Castillo, G Itchaki, J Paludo, M Varettoni, C Buske, TA Eyre, JC Chavez, ...
Blood, The Journal of the American Society of Hematology 133 (4), 299-305, 2019
|Tumor lysis, adverse events, and dose adjustments in 297 venetoclax-treated CLL patients in routine clinical practice|
LE Roeker, CP Fox, TA Eyre, DM Brander, JN Allan, SJ Schuster, ...
Clinical Cancer Research 25 (14), 4264-4270, 2019
|Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents|
LE Roeker, P Dreger, JR Brown, OB Lahoud, TA Eyre, DM Brander, ...
Blood advances 4 (16), 3977-3989, 2020
|Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post‐BCR inhibitor setting: a UK wide analysis|
TA Eyre, AA Kirkwood, S Gohill, G Follows, R Walewska, H Walter, ...
British journal of haematology 185 (4), 656-669, 2019
|NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome|
TA Eyre, R Clifford, A Bloor, L Boyle, C Roberts, M Cabes, GP Collins, ...
British journal of haematology 175 (1), 43-54, 2016
|Anaplastic lymphoma kinase‐positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease|
TA Eyre, D Khan, GW Hall, GP Collins
European journal of haematology 93 (6), 455-468, 2014
|Multiple myeloma in the very elderly patient: challenges and solutions|
J Willan, TA Eyre, F Sharpley, C Watson, AJ King, K Ramasamy
Clinical interventions in aging, 423-435, 2016
|Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy …|
TA Eyre, F Djebbari, AA Kirkwood, GP Collins
Haematologica 105 (7), 1914, 2020
|Efficacy of R‐BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy|
R McCulloch, C Visco, TA Eyre, R Frewin, N Phillips, DL Tucker, ...
British journal of haematology 189 (4), 684-688, 2020
|Time now to TORC the TORC? New developments in m TOR pathway inhibition in lymphoid malignancies|
TA Eyre, GP Collins, AH Goldstone, K Cwynarski
British journal of haematology 166 (3), 336-351, 2014
|COVID-19 in patients with CLL: improved survival outcomes and update on management strategies|
LE Roeker, TA Eyre, MC Thompson, N Lamanna, AR Coltoff, MS Davids, ...
Blood, The Journal of the American Society of Hematology 138 (18), 1768-1773, 2021
|Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia|
J Klintman, N Appleby, B Stamatopoulos, K Ridout, TA Eyre, P Robbe, ...
Blood, The Journal of the American Society of Hematology 137 (20), 2800-2816, 2021
|Stand‐alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R‐CHOP and is …|
TA Eyre, AA Kirkwood, J Wolf, C Hildyard, C Mercer, H Plaschkes, ...
British journal of haematology 187 (2), 185-194, 2019
|Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B‐cell lymphoma of the central nervous system–an international study of …|
E Schorb, CP Fox, B Kasenda, K Linton, N Martinez‐Calle, T Calimeri, ...
British Journal of Haematology 189 (5), 879-887, 2020